Market Overview
Sleep has quietly become one of the most closely tracked aspects of personal health, and the software built around it is turning into a serious business. The global sleep software market was valued at $776.2 million in 2023, grew to $878.9 million in 2024, and is projected to expand at a CAGR of 10.1%, reaching $1,569.2 million by 2030.
This growth is being driven largely by rising awareness of sleep health along with the increasing adoption of wearable technologies and AI-based solutions, with consumer apps and clinical healthcare tools acting as the two main engines of expansion. Expanding opportunities in emerging markets and the growing integration of Cognitive Behavioral Therapy (CBT) into sleep solutions are also fueling demand, as more consumers recognize the link between quality sleep and overall wellbeing.
Download PDF- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2133596
What Is Sleep Software?
At its core, sleep software refers to applications and platforms designed to monitor, manage, and improve sleep quality — spanning mobile apps, wearable device integrations, smart home connections, and other digital tools. These solutions typically draw on data such as sleep duration, patterns, environmental conditions, and other health metrics to generate insights or personalized recommendations.
Key Market Segments
By Region: North America dominated the market with a 42.6% share in 2024, largely on the back of high healthcare digitization and consumer wellness spending. However, Asia Pacific was the fastest-growing region in 2024, propelled by rising sleep-health awareness, increasing smartphone and wearable penetration, expanding healthcare digitalization, and government initiatives promoting mental wellness — particularly in markets like Japan, China, India, and Australia.
By Type: Integrated software is expected to post the highest CAGR at 11.5%, as unified platforms that pull data from wearables, medical devices, and mobile apps become more attractive to both clinicians and consumers.
By Offering: Applications are projected to grow at the fastest rate through 2030, reflecting the continued shift toward mobile- and web-based tools over standalone platforms.
By Function: Sleep improvement is expected to dominate the market, aided by consumer demand for behavioral interventions and guided relaxation programs rather than purely diagnostic tools.
By Indication: Sleep apnea is set to register the highest CAGR at 11.0%, reflecting both the scale of undiagnosed cases and rising digital-therapy adoption among patients already on CPAP or similar treatment.
By Deployment: Cloud-based models are expected to dominate, thanks to their scalability and ability to support real-time monitoring across devices.
By End User: Individual users represent the fastest-growing segment, underscoring how much of this market’s momentum comes from consumer self-care rather than institutional healthcare spending.
Market Drivers, Restraints, Opportunities, and Challenges
Driver: A large population of undiagnosed sleep apnea sufferers, combined with stress, obesity, and increasingly digital lifestyles, is expanding the pool of people seeking diagnostic and treatment tools — a trend with implications not just for consumer tech but for corporate wellness programs as well.
Restraint: Data privacy and security remain significant hurdles, since sleep apps collect sensitive biometric information that makes them attractive targets for cyberattacks; inadequate encryption and unclear data-sharing practices can erode user trust, especially under regulatory frameworks like GDPR and HIPAA.
Opportunity: The continued build-out of mobile health (mHealth) tools is opening new doors, as growing smartphone penetration lets sleep-tracking, chronic-disease management, and telemedicine features reach previously underserved regions.
Challenge: Monetization remains difficult for many sleep-app makers, since a lack of clinical validation leaves users skeptical about paying for premium features when free alternatives with similar tracking capabilities are widely available.
Competitive Landscape
The report identifies Koninklijke Philips N.V., Nihon Kohden Corporation, ResMed, Calm, and Sleep Cycle as “Star” players distinguished by strong innovation pipelines and broad market coverage. Calm leads the company evaluation matrix on the strength of its evidence-based sleep, meditation, and stress-management programs, along with deep integration with major wearable and mobile platforms, while Natus Medical is highlighted as an Emerging Leader thanks to its clinically validated diagnostics that combine polysomnography analytics with cloud-based data sharing and AI-assisted disorder detection for hospitals and sleep clinics.
Beyond the leaders, the market’s roster of key players also spans medical-device-oriented firms such as Cadwell Industries, Compumedics, Löwenstein Medical, CamNtech, Fisher & Paykel Healthcare, and Inspire Medical Systems, alongside consumer wellness names like Headspace.
Recent Developments
- December 2024: Calm partnered with the National Childbirth Trust (NCT), donating funds for meals and the organization’s infant feeding line, while also offering free access to lullabies and soundscapes to support maternal mental health.
- November 2024: Headspace Health acquired Sayana Inc., a startup that brings AI-driven chat and mood-tracking features to mobile apps, strengthening Headspace’s ability to personalize CBT, ACT, and DBT-based self-help tools.
- September 2024: ResMed rolled out new patient-centric features for sleep apnea therapy, including smartwatch compatibility and expanded myAir app capabilities such as sleep staging, aimed at improving CPAP engagement and delivering personalized coaching.
Outlook
Taken together, the data points to a market that is maturing quickly on two fronts at once: clinically validated diagnostic and therapy-management tools for conditions like sleep apnea and insomnia, and consumer-facing wellness apps competing on personalization, AI-driven insights, and integration with wearables. The rising role of cloud infrastructure and the incorporation of CBT-based interventions suggest that the next phase of growth will lean heavily on scalable, evidence-informed digital experiences rather than simple tracking features alone. For vendors, the central tension will be building enough clinical credibility to justify subscription pricing in a market still crowded with free alternatives.